What is Kailera Therapeutics's market cap?

Kailera Therapeutics (KLRA) has a market capitalization of $2.4B and trades on XNAS.

Where is Kailera Therapeutics headquartered?

Kailera Therapeutics is headquartered in United States of America. It has been publicly traded since 2026.

Kailera Therapeutics (KLRA) Stock Fundamentals & Financials

Kailera Therapeutics is a biotechnology company in the healthcare sector trading on XNAS, led by CEO Ronald C. Renaud Jr., with a market cap of $2.4B.

Market cap

$2.44B-23.6%

Net income-$78.9M-339%

EPS (diluted)-$3,650.00+79.7%

Quarterly · Q1 2026 · change vs. Q1 2025

Earnings

Next report

Aug 25, 2026 (In 2 weeks)

EPS estimate-$0.80

Financials

Q1 2026

Income statement

See full

Operating income-$84.7M-314%

Net income-$78.9M-339%

EPS (diluted)-$3,650.00+79.7%

Balance sheet

See full

Cash & equivalents$111.8M+9.9%

Total debt$10.5M—

Total equity-$432.1M-83.7%

Total assets$624.8M—

Cash flow

See full

Operating cash flow-$68.3M-275%

Profile

CountryUnited States of America

Listed2026

CEORonald C. Renaud Jr.

SectorHealthcare

IndustryBiotechnology

Websitekailera.com

FilingsSEC EDGAR

FAQ

What is Kailera Therapeutics's market cap?: Kailera Therapeutics (KLRA) has a market capitalization of $2.4B and trades on XNAS.
Where is Kailera Therapeutics headquartered?: Kailera Therapeutics is headquartered in United States of America. It has been publicly traded since 2026.